Trial Profile
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Baxalta; Shire; Takeda
- 07 Oct 2020 Status changed from active, no longer recruiting to completed.
- 27 Apr 2020 Planned End Date changed from 31 Aug 2020 to 31 Jul 2020.
- 27 Apr 2020 Planned primary completion date changed from 31 Aug 2020 to 31 Jul 2020.